Triennial review of drugs

Every three years the FOPH reviews all pharmaceuticals on the specialities list to check whether they still meet the requirements for inclusion.

Triennial review of pharmaceuticals in 2019

Triennial review of pharmaceuticals in 2018

Lists of the pharmaceuticals with a reduced price and lists of known pharmaceuticals without a price reduction as of 1 February 2019, subject to possible changes.

The price reductions ordered by the FOPH as of 1 February 2019, which are the object of appeals in the Federal Administrative Court, are not listed. The names of those pharmaceuticals in question will be published in a separate list when the Federal Administrative Court has informed the FOPH on the appeal.


The FOPH has completed the review of the majority of pharmaceuticals and has ordered possible price reductions as of 1 December 2018. The review of the remaining pharmaceuticals can be completed by the beginning of 2019. Further price reductions will be ordered as of 1 February 2019.

Lists of the pharmaceuticals with a reduced price and lists of known pharmaceuticals without a price reduction as of 1 December 2018, subject to possible changes.

The price reductions ordered by the FOPH as of 1 December 2018, which are the object of appeals in the Federal Administrative Court, are not listed. The names of those pharmaceuticals in question will be published in a separate list when the Federal Administrative Court has informed the FOPH on the appeal.

List of pharmaceuticals subject to appeal

The pharmaceuticals which were the object of appeals in the Federal Administrative Court are published in the List of pharmaceuticals subject to an appeal against a decision of the FOPH (see page Information related to the specialities list).

Triennial review of drugs in 2017

Complete list of the pharmaceuticals with a reduced price (as reviewed in 2017) and lists of the pharmaceuticals without a price reduction (as reviewed in 2017), subject to possible changes.

General information

Pharmaceuticals are assigned to one of three groups based on the therapeutic group of the specialities list they belong to. Each group is reviewed every three years:

Group A Group B Group C

Gastroenterology (04)

Metabolism (07)

Antidotes (15)

Cation exchangers (16)

Gastroenterology, complementary medicine (54)

Metabolism, complementary medicine (57)

Nervous system (01)

Kidneys and water balance (05)

Blood (06)

Dermatology (10)

Odontostomatology (13)

Diagnostics (14)

Nervous system, complementary medicine (51)

Kidneys and water balance, complementary medicine (55)

Blood, complementary medicine (56)

Dermatology, complementary medicine (60)

Cardiovascular (02)

Pulmonary and respiratory (03)

Infectious diseases (08)

Gynaecology (09)

Ophthalmology (11)

Otorhinolaryngology (12)

Cardiovascular, complementary medicine (52)

Pulmonary and respiratory, complementary medicine (53)

Infectious diseases, complementary medicine (58)

Gynaecology, complementary medicine (59)

Ophthalmology, complementary medicine (61)

Otorhinolaryngology, complementary medicine (62)

Current notifications from the FOPH on the triennial review of inclusion requirements for pharmaceuticals



Last modification 10.01.2019

Top of page

Contact

Federal Office of Public Health FOPH
Division of Health Care Services
Pharmaceuticals Section
Schwarzenburgstrasse 157
3003 Berne
Switzerland
Tel. +41 58 462 90 35
E-mail

Print contact

https://www.bag.admin.ch/content/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/Arzneimittel/Ueberpruefung-der-Aufnahmebedingungen-alle-drei-Jahre.html